Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Huakang Biomedical Holdings Company Limited (8622) Stock Price & Analysis

0 Followers

8622 Stock Chart & Stats

HK$0.29HK$0.02(7.55%)
At close: 4:00 PM GMT+8
HK$0.15HK$0.2HK$0.25Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 0.27 - HKD 0.29
52-Week Range
HKD 0.15 - HKD 0.58
Previous Close
HKD 0.27
Volume
N/A
Average Volume (3M)
231.47K
Market Cap
HKD 136.60M
Enterprise Value
HKD 67.16M
Total Cash (Recent Filing)
HKD 39.23M
Total Debt (Recent Filing)
HKD 7.66M
Price to Earnings (P/E)
―
Beta
0.48
Next Earnings
Mar 25, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth

Rapid revenue expansion indicates growing demand and improving market reach, giving the company a larger base from which to develop operating scale. If sustained, this growth can support stronger earnings potential, although profitability conversion remains necessary.

High Gross Margins

Consistently high gross margins point to favorable underlying product economics and provide meaningful room to cover operating expenses. This margin profile can support future profitability if revenue growth eventually produces sufficient operating leverage and disciplined cost management.

Manageable Leverage

Low leverage reduces balance-sheet pressure and preserves flexibility for the company to fund operations or pursue growth without relying heavily on additional borrowing. Steady assets and equity also suggest the balance sheet has not materially deteriorated despite current losses.

Bears Say

Persistent Operating Losses

The company remains materially unprofitable despite strong revenue growth, showing that increased sales have not yet translated into adequate operating leverage. Continued losses could limit internally funded expansion and require management to prioritize a credible path toward break-even.

Recurring Cash Burn

Negative operating and free cash flow indicate that the business is consuming cash rather than funding itself through operations. Although cash-flow growth improved from a negative base, recurring burn can reduce financial flexibility and increase dependence on external funding if it persists.

Negative Returns On Equity

Negative return on equity shows that the company is not currently generating profits from shareholder capital, weakening the effectiveness of its balance sheet. Unless earnings improve, continued losses may erode the economic value of invested capital and constrain long-term reinvestment.

8622 FAQ

What was Huakang Biomedical Holdings Company Limited’s price range in the past 12 months?
Huakang Biomedical Holdings Company Limited lowest stock price was HK$0.15 and its highest was HK$0.58 in the past 12 months.
What is Huakang Biomedical Holdings Company Limited’s market cap?
Huakang Biomedical Holdings Company Limited’s market cap is HK$136.60M.
When is Huakang Biomedical Holdings Company Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Huakang Biomedical Holdings Company Limited’s earnings last quarter?
Huakang Biomedical Holdings Company Limited released its earnings results on Aug 28, 2026. The company reported -HK$0.005 earnings per share for the quarter.
Is Huakang Biomedical Holdings Company Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Huakang Biomedical Holdings Company Limited pay dividends?
Huakang Biomedical Holdings Company Limited does not currently pay dividends.
What is Huakang Biomedical Holdings Company Limited’s EPS estimate?
Huakang Biomedical Holdings Company Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Huakang Biomedical Holdings Company Limited have?
Huakang Biomedical Holdings Company Limited has 515,472,000 shares outstanding.
What happened to Huakang Biomedical Holdings Company Limited’s price movement after its last earnings report?
Huakang Biomedical Holdings Company Limited reported an EPS of -HK$0.005 in its last earnings report. Following the earnings report the stock price went up 3.125%.
Which hedge fund is a major shareholder of Huakang Biomedical Holdings Company Limited?
Currently, no hedge funds are holding shares in HK:8622
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology